IP Library Granted Patent US 11,162,129
Granted Patent B2
US 11,162,129 · App. 15/799,139 · Granted Nov 2, 2021

Photoprotective mixtures as imaging reagents in sequencing-by-synthesis

Inventors: Luisa Andruzzi (Concord, MA); Michel Georges Perbost (Belmont, MA); Dona Hevroni (Lexington, MA); Minakshi Guha (Wakefield, MA); Austin Ricker (Waltham, MA); Timothy Pelletier (Fitchburg, MA)
Assignee: IsoPlexis Corporation
C12Q1/6806C07C215/28C07D311/66C12Q1/6816C12Q1/6874G01N33/582C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,162,129
App. No.
15/799,139
Granted
Nov 2, 2021
Kind
B2
Abstract

The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. In particular, the present invention contemplates the use of photoprotective mixture of compounds as imaging reagents to improve stability and storage of fluorescent compounds, including but not limited to, nucleotides with fluorescent labels.

Claims (23)

1. A method of incorporating labeled nucleotides, comprising:

a) providing;

i) a plurality of nucleic acid primers and template molecules,

ii) a polymerase,

iii) a first imaging reagent comprising a mixture of at least one fluorescence quenching inhibitor, at least one antioxidant, and at least one radical scavenger compound, and

iv) a plurality of nucleotide analogues wherein at least a portion of said nucleotide analogues is labeled with a label attached through a cleavable linker to the base;

b) hybridizing at least a portion of said primers to at least a portion of said template molecules so as to create hybridized primers;

c) incorporating a first labeled nucleotide analogue with said polymerase into at least a portion of said hybridized primers so as to create extended primers comprising an incorporated labeled nucleotide analogue; and

d) imaging said incorporated labeled nucleotide analogue in the presence of said first imaging reagent.

2. The method of claim 1 , wherein said at least one fluorescence quenching inhibitor is 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

3. The method of claim 1 , wherein said at least one antioxidant is selected from the group consisting of gentisic acid, protocatechuic acid and protocatechuate ethyl ester.

4. The method of claim 1 , wherein said at least one radical scavenger compound is carnitine.

5. The method of claim 1 , further comprising step (e) incorporating a second nucleotide analogue with said polymerase into at least a portion of said extended primers.

6. The method of claim 1 , wherein said label is fluorescent.

7. An imaging reagent comprising:

i) 2-Amino-2-hydroxymethyl-propane-1,3-diol (TRIS) HCl buffer;

ii) carnitine ranging in concentration between approximately 5-50 mM;

iii) 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid ranging in concentration between approximately 5-15 mM;

iv) 2,5 dihydroxybenzoic acid ranging in concentration between approximately 10-50 mM; and

v) 3,4, dihydroxybenzoic acid ethyl ester ranging in concentration between approximately 10-20 mM.

8. The method of claim 1 , wherein said at least one antioxidant comprises gentisic acid, said at least one radical scavenger compound comprises carnitine, and said at least one fluorescence quenching inhibitor comprises 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

9. The method of claim 1 , wherein said at least one antioxidant comprises protocatechuic acid ethyl ester, said at least one radical scavenger compound comprises carnitine, and said at least one fluorescence quenching inhibitor comprises 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

10. The method of claim 1 , wherein said imaging delivers an average read length that is substantially similar to a read length obtained when said first imaging reagent is replaced by a second imaging reagent comprising 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, glucose oxidase, glucose, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 24, 2023
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: ISOPLEXIS CORPORATION
Reel/Frame 063235/0942 →
PATENT PURCHASE AGREEMENT Recorded Jul 30, 2021
From: QIAGEN SCIENCES, LLC
To: ISOPLEXIS CORPORATION
Reel/Frame 057043/0629 →
SECURITY AGREEMENT Recorded May 28, 2021
From: ISOPLEXIS CORPORATION
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 056421/0929 →
MERGER Recorded Oct 31, 2018
From: QIAGEN WALTHAM, INC.
To: QIAGEN SCIENCES, LLC
Reel/Frame 047372/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2018
From: ANDRUZZI, LUISA; PERBOST, MICHEL GEORGES; HEVRONI, DONA; GUHA, MINAKSHI; RICKER, AUSTIN; PELLETIER, TIMOTHY
To: QIAGEN WALTHAM, INC.
Reel/Frame 046911/0742 →
Continuity (2)
Provisional Application 62419702 · Nov 9, 2016
Related Publication 20180127809A1 · May 10, 2018